TICKERNERD
Menu
REPLREPLHealthcare · Biotechnology

REPL Stock Forecast: Replimune Group, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$13
−1.21% on the day

The 8 Wall Street analysts covering Replimune Group, Inc. hold a median 12-month price target of $20 — +49.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
39 / 100
Median analyst target
$20
Analysts covering
8
Revenue$0.0
Operating income−$68.0M
Net income−$69.8M
Free cash flow−$75.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.0%
1M
−11.7%
YTD
+34.2%
1Y
+185.3%
From 52W high
−18.4%
From 52W low
+667.1%
$2
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

REPL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Replimune Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
86
Value
75
Accruals
69
Growth
55
Size
41
Revisions
35
Quality
33
Issuance
12
Volatility
10

Momentum (86): The shares have been drifting up relative to others.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

REPL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on REPL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26REPLHigh $24Median $20Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy0 Hold1 Sell
Low $14Median $20High $24

The green dot is the last close — the median target sits +49.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
26 Aug 2026JP MorganMaintainsOverweight$20 → $21
7 Aug 2026JP MorganMaintainsOverweight—
7 Aug 2026JP MorganMaintainsOverweight$17 → $20
7 Aug 2026WedbushUpgradeOutperform—
7 Aug 2026WedbushUpgradeOutperform$12 → $19
4 Aug 2026Leerink PartnersUpgradeOutperform—
4 Aug 2026Leerink PartnersUpgradeOutperform$11 → $17
31 July 2026Cantor FitzgeraldUpgradeOverweight—
31 July 2026Cantor FitzgeraldUpgradeOverweight—
31 July 2026WedbushMaintainsNeutral—
31 July 2026WedbushMaintainsNeutral$9.00 → $12
30 June 2026WedbushMaintainsNeutral$6.00 → $9.00
30 June 2026WedbushMaintainsNeutral—
26 June 2026JP MorganUpgradeOverweight—
1 June 2026WedbushMaintainsNeutral—
29 May 2026JP MorganUpgradeNeutral—
13 Apr 2026Cantor FitzgeraldDowngradeNeutral—
13 Apr 2026HC Wainwright & Co.DowngradeSell—
13 Apr 2026JefferiesDowngradeHold—
13 Apr 2026JP MorganDowngradeUnderweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. REPL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

REPL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Replimune Group, Inc. returned +185.3% against +16.2% for the S&P 500, dividends included.

REPL vs S&P 500, last 12 monthsTotal return, rebased to 100
0100200300400Jan 26Apr 26Jul 26Oct 26REPLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

REPL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Replimune Group, Inc. (REPL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.9×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
10.5×

Cheaper than 9% of US stocks

EV / EBITDA
−4.0×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−134.3%

Higher than 11% of US stocks

Return on assets
−51.3%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Replimune Group, Inc. (REPL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Replimune Group, Inc. has a market value of $1.2B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$297.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$280.5M.

  • Shares outstanding: 84.0M.

  • Trailing P/E: −3.9×; forward P/E: −7.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Replimune Group, Inc. employs 465 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

REPL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
REPLReplimune Group, Inc.$1.2B
39
KLRAKailera Therapeutics, Inc.$1.2B
1
DMRADamora Therapeutics, Inc.$1.2B
36
ORICOric Pharmaceuticals, Inc.$1.2B
49
DRTSAlpha Tau Medical Ltd.$1.3B
15
KARDKardigan, Inc.$1.3B
0
AVLNAvalyn Pharma, Inc.$1.1B
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Replimune Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest REPL news & analysis

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

GlobeNewsWire · 5 Oct 2026negative

A shareholder lawsuit has been filed against Replimune Group, with a lead plaintiff deadline of October 5, 2026. The suit relates to the FDA's April 2026 rejection of Replimune's RP1 resubmission, in which the agency stated that previously communicated study design concerns were never addressed; Replimune had told investors the resubmission was a complete response and that commercial launch teams were ready, and REPL shares fell to $1.70.

Why it matters — Replimune watchers would care because the FDA rejection of the RP1 resubmission, the significant share decline, and the resulting shareholder lawsuit raise regulatory and legal risks around the company's lead product candidate.

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

GlobeNewsWire · 1 Oct 2026positive

Replimune announced that TUDRIQEV is now available in the U.S. for advanced melanoma. The company has also launched ReplimuneConnect Plus, a program offering dedicated support and resources to help eligible patients access TUDRIQEV.

Why it matters — The commercial availability of TUDRIQEV in the U.S. and the launch of a patient support program mark a key step for Replimune in bringing its therapy to the market for advanced melanoma patients.

Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1

Newsfile Corp · 28 Sept 2026negative

Robbins LLP announced that a class action has been filed against Replimune Group, Inc. on behalf of investors who acquired the company's securities between October 20, 2025 and April 10, 2026, alleging that the company misled investors regarding the efficacy and viability of its lead product candidate RP1.

Why it matters — A class action alleging investor deception over its lead product candidate RP1 introduces potential legal and reputational risk for Replimune and its shareholders.

FAQ

Frequently asked questions about REPL stock

What is the REPL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Replimune Group, Inc. have a median 12-month price target of $20, with estimates ranging from $14 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is REPL stock a buy right now?

Of the 8 analysts covering Replimune Group, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Replimune Group, Inc. 39 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank REPL?

As at 8 Oct 2026, Replimune Group, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (86 of 100).

Will REPL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +49.5% from the last close, and Ticker Nerd's factor model ranks Replimune Group, Inc. 39 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the REPL stock forecast for 2030?

No analyst covering Replimune Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REPL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $24 over the next 12 months.

How has REPL stock performed over the past year?

Replimune Group, Inc. returned +185.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Replimune Group, Inc. do?

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer.

What is the latest news on REPL?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL". A shareholder lawsuit has been filed against Replimune Group, with a lead plaintiff deadline of October 5, 2026. The suit relates to the FDA's April 2026 rejection of Replimune's RP1 resubmission, in which the agency stated that previously communicated study design concerns were never addressed; Replimune had told investors the resubmission was a complete response and that commercial launch teams were ready, and REPL shares fell to $1.70.

Company

About Replimune Group, Inc.

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product pipeline includes therapies built on its proprietary RPx platform, with candidates aimed at multiple cancer settings. Replimune Group, Inc. serves the oncology market by advancing biologic approaches intended to complement or expand existing cancer treatment options. Headquartered in Woburn, Massachusetts, and founded in 2015, the company operates in the United States and the United Kingdom, with an emphasis on research, development, and commercialization of cancer immunotherapy programs.

CEO Dr. Sushil Patel Ph.D. · 465 employees · United States · https://www.replimune.com